Related Experiment Video

Updated: Jan 25, 2026

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
10:52

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence

Published on: December 23, 2022

5.6K

[Percutaneous treatment of atrial septal defect and patent foramen ovale]

M Lempereur1, P Lancellotti2

  • 1Service de Cardiologie, CHU Liège, Belgique.

Revue Medicale De Liege
|May 10, 2019
PubMed

Insights

Atrial septal defect (ASD) and patent foramen ovale (PFO) are common heart conditions. Percutaneous closure is a recommended therapy for ASD and increasingly for PFO to prevent stroke.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Congenital Heart Disease

Background:

  • Atrial septal defect (ASD) is a common congenital heart disease leading to right heart volume overload and increased morbidity/mortality.
  • Patent foramen ovale (PFO) persists in ~25% of adults, potentially causing paradoxical embolism and cryptogenic stroke.

Purpose of the Study:

  • To discuss the indications and procedures for percutaneous closure of ASD secundum-type.
  • To review the emerging role of percutaneous PFO closure for cryptogenic stroke prevention.

Main Methods:

  • Percutaneous closure of secundum-type ASD as a first-line therapy.
  • Percutaneous closure of PFO in patients with cryptogenic stroke.

Main Results:

  • Percutaneous ASD closure is a recommended first-line therapy.
  • Percutaneous PFO closure shows a modest but significant decrease in stroke recurrence risk.

Conclusions:

  • Percutaneous closure is an effective treatment for ASD secundum-type.
  • Percutaneous PFO closure is a beneficial option for select patients experiencing cryptogenic stroke.

Keywords:
Atrial septal defectPatent foramen ovaleStructural heart diseasePercutaneous cardiac intervention

More Related Videos

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

4.3K
Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter08:00

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter

Published on: June 15, 2015

14.4K

Related Concept Videos

Lumber Defects01:23

Lumber Defects

Lumber defects, which can affect both the appearance and structural integrity of wood, include a variety of growth and manufacturing flaws. Growth defects such as knots and knotholes occur where branches were once attached to the tree trunk, with knotholes forming when these knots fall out. Other natural defects include decay and insect damage, which compromise the wood's strength and durability.
Shakes are minor fractures that run along or across the wood's annual rings, while wane is...
490
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
503
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
850
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
973
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K